Moleculin Biotech, Inc. — Q1 2019 Form 10-Q
Business context and reporting period. The company is a clinical-stage oncology drug developer with no product revenue. This summary covers the three months ended March 31, 2019; balance-sheet comparisons are with December 31, 2018. Its pipeline included Annamycin and WP1066 in clinical trials, and WP1220 entered clinical testing in Poland during the quarter. The company reported three drugs across four clinical trials.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 or comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.932 million | $1.237 million |
| General and administrative expense | $1.591 million | $1.392 million |
| Total operating expenses | $4.571 million | $2.637 million |
| Net loss | $4.041 million | $1.927 million |
| Basic and diluted loss per share | $0.14 | $0.08 |
| Cash used in operations | $3.847 million | $2.807 million |
| Cash and cash equivalents, at quarter-end | $8.782 million | $7.134 million at Dec. 31, 2018 |
| Current assets / current liabilities | $9.613 million / $6.436 million | $7.974 million / $3.878 million at Dec. 31, 2018 |
| Total liabilities | $6.616 million | $5.313 million at Dec. 31, 2018 |
No debt balance is reported in the presented balance sheet. The company had no meaningful revenue or gross margin from which to assess profitability margins. Its $0.529 million gain from remeasuring warrant liabilities was noncash and reduced reported net loss; the liability was $2.386 million at quarter-end. Working capital was approximately $3.177 million.
Material changes and financing
- R&D expense increased by approximately $1.7 million year over year, which management attributed mainly to increased clinical activity and a modest increase in R&D headcount. G&A expense rose approximately $0.2 million, primarily due to payroll and stock-based compensation.
- Operating cash use increased by approximately $1.0 million year over year, reflecting drug development, manufacturing and testing, staffing, sponsored research, and license fees.
- The company raised approximately $5.25 million gross in a March underwritten offering of 5.25 million units, each including one common share and half a warrant. Net proceeds were approximately $4.65 million. Share count increased to 34.409 million at quarter-end from 28.529 million at year-end; additional warrants create potential dilution.
- After quarter-end, an April offering raised approximately $15.0 million gross through 9.375 million units, each including one share and half a warrant. The company also received approximately $1.6 million from warrant exercises through the filing date.
Outlook, risks and unusual items
- Runway and going concern: Management estimated that quarter-end cash plus subsequent equity proceeds would fund planned operations into the second quarter of 2020, subject to spending, enrollment, stock price, and market conditions. Separately, the financial-statement note says substantial doubt exists about the company’s ability to continue as a going concern, given its accumulated deficit of $30.4 million, absence of operating revenue, and dependence on financing and eventual profitability. The filing cautions that further capital may be needed and may not be available on acceptable terms.
- Clinical and development risks: The company depends on successful trials, patient recruitment, regulatory approvals, third-party manufacturers and research providers, and continued access to licensed intellectual property. Management reported slow U.S. Annamycin recruitment and noted it cannot assure timely enrollment or trial completion. WP1732’s expected U.S. IND filing moved to 2020.
- Clinical updates: In March, the company reported that four U.S. Annamycin patients completed treatment at 100 mg/m² and that the trial would proceed to 120 mg/m². In May, after quarter-end, it reported that two of three patients in the first Polish cohort responded sufficiently to qualify for possible bone-marrow transplant; no cardiotoxicity had been reported in either trial. These are interim, early-stage results, not established efficacy.
- Other post-quarter developments: The FDA granted Fast Track Designation to Annamycin for relapsed or refractory AML in April. These developments occurred after the reporting date and should not be treated as Q1 results.
- Related-party and contingent arrangements: In February, the company sublicensed rights to WPD Pharmaceuticals, which is affiliated with a founder and major shareholder, and to Animal Life Sciences, also affiliated with that individual; the company received a 10% membership interest in ALI. The company said future royalty revenue from these arrangements was uncertain. It paid $1.0 million on April 30 to repurchase rights under the HPI agreement; the amount had been accrued at March 31 and expensed in 2018.
- Controls and accounting: Management determined disclosure controls were not effective because of a material weakness in segregation of accounting duties. It described staffing, system, and process improvements but did not report remediation as complete. The company adopted the new lease standard on January 1, 2019, recognizing a $0.106 million right-of-use asset and $0.213 million of lease liabilities at quarter-end.
Important facts for investors to verify
- Whether cash runway assumptions remain consistent with the stated going-concern uncertainty, and what additional financing may be required.
- Trial enrollment, dose escalation, safety, and independently substantiated efficacy results for Annamycin, WP1066, and WP1220.
- The extent of potential dilution from issued shares, outstanding warrants, and future equity financing.
- Whether the material weakness in segregation of duties has been fully remediated.
- The terms, related-party safeguards, development obligations, and potential economics of the WPD and ALI sublicenses.